BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25348872)

  • 1. Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays.
    Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi T; Taira T; Ono A; Maniwa T; Takahashi S; Mori K; Endo M; Abe M; Hayashi I; Nakajima T; Ohde Y; Yamamoto N
    BMC Cancer; 2014 Oct; 14():786. PubMed ID: 25348872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
    Serizawa M; Koh Y; Kenmotsu H; Isaka M; Murakami H; Akamatsu H; Mori K; Abe M; Hayashi I; Taira T; Maniwa T; Takahashi T; Endo M; Nakajima T; Ohde Y; Yamamoto N
    Cancer; 2014 May; 120(10):1471-81. PubMed ID: 24700479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of small cell lung cancer in a Japanese cohort.
    Wakuda K; Kenmotsu H; Serizawa M; Koh Y; Isaka M; Takahashi S; Ono A; Taira T; Naito T; Murakami H; Mori K; Endo M; Nakajima T; Ohde Y; Takahashi T; Yamamoto N
    Lung Cancer; 2014 May; 84(2):139-44. PubMed ID: 24657128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations.
    Rekhtman N; Paik PK; Arcila ME; Tafe LJ; Oxnard GR; Moreira AL; Travis WD; Zakowski MF; Kris MG; Ladanyi M
    Clin Cancer Res; 2012 Feb; 18(4):1167-76. PubMed ID: 22228640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplexed molecular profiling of lung cancer using pleural effusion.
    Akamatsu H; Koh Y; Kenmotsu H; Naito T; Serizawa M; Kimura M; Mori K; Imai H; Ono A; Shukuya T; Taira T; Murakami H; Ohde Y; Endo M; Nakajima T; Takahashi T; Yamamoto N
    J Thorac Oncol; 2014 Jul; 9(7):1048-1052. PubMed ID: 24926551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The introduction of systematic genomic testing for patients with non-small-cell lung cancer.
    Cardarella S; Ortiz TM; Joshi VA; Butaney M; Jackman DM; Kwiatkowski DJ; Yeap BY; Jänne PA; Lindeman NI; Johnson BE
    J Thorac Oncol; 2012 Dec; 7(12):1767-1774. PubMed ID: 23154547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas.
    Wang R; Pan Y; Li C; Zhang H; Garfield D; Li Y; Ye T; Hu H; Luo X; Li H; Zhang Y; Zhang J; Zhou X; Shen L; Pao W; Sun Y; Chen H
    J Thorac Oncol; 2014 Jun; 9(6):760-8. PubMed ID: 24481316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
    Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
    Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
    Liu J; Liu Y
    Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung.
    Kang SM; Kang HJ; Shin JH; Kim H; Shin DH; Kim SK; Kim JH; Chung KY; Kim SK; Chang J
    Cancer; 2007 Feb; 109(3):581-7. PubMed ID: 17186532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker expression and druggable gene alterations for development of an appropriate therapeutic protocol for pulmonary adenosquamous carcinoma.
    Watanabe Y; Shiraishi K; Takahashi F; Yoshida A; Suzuki K; Asamura H; Takeuchi M; Furuta K; Tsuta K
    Histopathology; 2015 Jun; 66(7):939-48. PubMed ID: 25257380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
    Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
    Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
    Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
    Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion.
    Wu SG; Liu YN; Yu CJ; Yang JC; Shih JY
    Genes Chromosomes Cancer; 2018 Oct; 57(10):513-521. PubMed ID: 30107055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of a spectrum of driver genes in female Chinese patients with advanced or metastatic squamous cell carcinoma of the lung.
    Qiong Z; Na WY; Bo W; Zhu Z; Ling P; Bo MH; Min TY; Lei Z; Na HD; Bo Z; Fang LJ; Seng ZS
    Lung Cancer; 2015 Feb; 87(2):117-21. PubMed ID: 25488863
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive analysis of oncogenic mutations in lung squamous cell carcinoma with minor glandular component.
    Pan Y; Wang R; Ye T; Li C; Hu H; Yu Y; Zhang Y; Wang L; Luo X; Li H; Li Y; Shen L; Sun Y; Chen H
    Chest; 2014 Mar; 145(3):473-479. PubMed ID: 24158231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies.
    Forest F; Yvorel V; Karpathiou G; Stachowicz ML; Vergnon JM; Fournel P; Tiffet O; Trombert B; Péoc'h M
    Hum Pathol; 2016 Mar; 49():99-106. PubMed ID: 26826416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.